microRNAs and their therapeutic strategy in phase I and phase II clinical trials

被引:11
|
作者
Ameya, K. P. [1 ]
Kaliaperumal, Kumaravel [2 ]
Sekar, Durairaj [1 ]
机构
[1] Saveetha Univ, Saveetha Dent Coll & Hosp, Saveetha Inst Med & Tech Sci SIMATS, RNA Biol Lab, Chennai 600077, India
[2] Saveetha Univ, Saveetha Dent Coll, Dept Orthodont, Unit Biomat Res, Chennai 600077, Tamil Nadu, India
关键词
clinical trials; diseases; miRNAs; miRNA therapeutics; signaling pathway; CANCER; DELIVERY; BIOMARKERS; PATHWAY; DISEASE; DRUG;
D O I
10.2217/epi-2023-0363
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
miRNAs play a crucial therapeutic role in diseases such as cancer, diabetes and viral infections, with around 1900 identified in the human genome. Some have progressed to clinical trials, and miRNA mimics and miRNA inhibitors are pivotal therapeutic molecules undergoing evaluation. The review delves into various miRNA-associated clinical trials, emphasizing their precision in targeting specific genes, modulating disease pathways and diagnostic potential. This underscores the importance of miRNA therapy, foreseeing innovations in precision medicine techniques for diverse diseases. The future envisions improved delivery systems addressing challenges like immunogenicity and digestion, while a comprehensive miRNA-based omics database could guide the development of tailored antisense miRNAs, further advancing precision medicine strategies.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] Coaching intervention as a strategy for enhancing accrual to phase I/II clinical trials
    Fracasso, P. M.
    Walker, M. S.
    Mathews, K. J.
    Morgan, H. P.
    Goodner, S. A.
    Foster, D. M.
    Hardmon, A. A.
    Creekmore, A. N.
    Springer, B. C.
    Fisher, E. B.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [2] Phase I and II clinical trials of trastuzumab
    Baselga, J
    ANNALS OF ONCOLOGY, 2001, 12 : 49 - 55
  • [3] Phase I and II clinical trials for the mucopolysaccharidoses
    Poswar, Fabiano
    Baldo, Guilherme
    Giugliani, Roberto
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2017, 26 (12) : 1331 - 1340
  • [4] Investigational drugs in phase I and phase II clinical trials for thalassemia
    Motta, Irene
    Scaramellini, Natalia
    Cappellini, Maria Domenica
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2017, 26 (07) : 793 - 802
  • [5] Drugs in phase I and phase II clinical trials for systemic sclerosis
    Chung, Melody P.
    Chung, Lorinda
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2020, 29 (04) : 349 - 362
  • [6] An update on bronchodilators in Phase I and II clinical trials
    Cazzola, Mario
    Rogliani, Paola
    Segreti, Andrea
    Matera, Maria Gabriella
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2012, 21 (10) : 1489 - 1501
  • [7] Phase I and II Clinical Trials for Gastric Cancer
    Khushalani, Nikhil I.
    SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA, 2012, 21 (01) : 113 - +
  • [8] Investigational drugs in phase I and phase II clinical trials for hereditary angioedema
    Farkas, Henriette
    Debreczeni, Marta Lidia
    Kohalmi, Kinga Viktoria
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2018, 27 (01) : 87 - 103
  • [9] Investigational HIV integrase inhibitors in phase I and phase II clinical trials
    Han, Yingshan
    Mesplede, Thibault
    Wainberg, Mark A.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2017, 26 (11) : 1207 - 1213
  • [10] Operation strategy of Phase I trials
    Ishizuka, N.
    Taniguchi, T.
    EJC SUPPLEMENTS, 2008, 6 (12): : 121 - 121